Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

Bilal A Siddiqui,1 Jinesh S Gheeya,2 Rohit Goswamy,2 Tharakeswara K Bathala,3 Devaki Shilpa Surasi,4 Jianjun Gao,1 Amishi Shah,1 Matthew T Campbell,1 Pavlos Msaouel,1,5 Sangeeta Goswami,1,6 Jennifer Wang,1 Amado J Zurita,1 Eric Jonasch,1 Paul G Corn,1 Ana M Aparicio,1 Arlene O Siefker-Radtke,1 Padmanee Sharma,1,6 Sumit K Subudhi,1 Nizar Tannir1

ABSTRACT

Background Immune checkpoint therapy (ICT) prolongs survival in subsets of patients with cancer but can also trigger immune-related adverse events (irAEs) requiring treatment discontinuation. Recent studies have investigated safety of ICT rechallenge after irAEs, and evidence suggests that rechallenge may be associated with improved antitumor responses. However, data are limited on response duration after ICT rechallenge, particularly after severe irAEs.

Objective To evaluate safety and efficacy of ICT rechallenge after moderate-to-severe irAEs in patients with renal cell carcinoma (RCC), urothelial carcinoma (UC), and prostate cancer.

Methods In this retrospective cohort study, medical records from September 25, 2013, to June 1, 2020, for patients with genitourinary (GU) cancers at MD Anderson Cancer Center who were rechallenged with the same or different ICT following irAEs were reviewed. Demographics, ICT exposure, irAEs (grade and treatment), ICT discontinuation or rechallenge, rates of subsequent irAEs (new or recurrent) and antitumor activity (objective response rates and response duration) were reviewed.

Results Sixty-one patients with RCC, UC, and prostate cancer were rechallenged with ICT after experiencing 105 total irAEs. Objective response rates after rechallenge, that is, upgrade in response, were 14% in RCC (4/28), 21% in UC (3/14), and 0% in prostate cancer. All seven patients who achieved upgrade in response had initial grade 2 or 3 irAEs. Responses were durable among these seven patients, with median radiographic progression-free survival not reached (range: 3.7–66.4 months) as of the March 8, 2021, data cut-off (median follow-up 40.9 months (95% CI 35.3 to 46.5)). All achieved complete response except one patient who was lost to follow-up. The rate of subsequent grade 3 or 4 irAEs after rechallenge was 30%, with no fatal irAEs. The rate of recrudescence of the same irAE was 26% (16/61). 54% of patients received corticosteroids (33/61), and 21% received targeted immunosuppression (13/61) for the initial irAEs.

Conclusions and relevance ICT rechallenge after moderate-to-severe irAEs was associated with deep and durable responses in a subset of patients with RCC and UC, with acceptable safety and no fatal events. Strategies to enable ICT resumption after moderate-to-severe irAEs, such targeted immunosuppression, warrant further study.

INTRODUCTION

Immune checkpoint therapies (ICTs), most commonly targeting cytotoxic T lymphocyte-associated protein-4 (CTLA-4), programmed cell death protein-1 (PD-1), and/or programmed death-ligand 1 (PD-L1) have dramatically altered the treatment paradigm for many cancers, offering prolonged survival for subsets of patients. ICTs are standard-of-care therapy for patients with renal cell carcinoma (RCC) and urothelial carcinoma (UC).1,2

ICTs carry the risk of immune-related adverse events (irAEs), in which excess immune activation can lead to damage of normal host tissue. Though irAEs most commonly affect the skin, gastrointestinal tract and endocrine systems, irAEs can affect any organ including cardiovascular, pulmonary, musculoskeletal and nervous systems, among others. irAEs vary in severity, ranging from mild events in which ICT can often be continued to severe irAEs warranting cessation of therapy and aggressive immunosuppression. In general, management guidelines recommend continuation of ICT for most grade 1 irAEs (defined by the Common Terminology Criteria for Adverse Events...
(CTCAE)), whereas grade 2 irAEs usually warrant ICT interruption, treatment with corticosteroids, and consideration of ICT resumption when the irAE returns to grade 1 or has resolved. Grade 3 irAEs typically require high-dose corticosteroids in addition to withholding ICT and often involve additional, targeted immunosuppression.

Multiple studies have demonstrated a link between manageable, non-fatal irAEs and improved outcomes in patients with cancer. The mechanisms of these augmented antitumor outcomes are incompletely defined, but may be due in part to shared antigens between host and tumor, which may enable effective antitumor T cell responses within the context of excess immune activation during irAEs. Importantly, such studies have often reported that immunosuppressive treatment of irAEs does not necessarily reduce the antitumor efficacy of ICTs. However, prolonged exposure to high-dose corticosteroids is associated with serious adverse effects, including life-threatening opportunistic infection, hyperglycemia, and myopathy, among others, highlighting the need for steroid-sparing immunosuppression to abrogate the toxicity. In certain cases, rechallenge with ICTs has been associated with antitumor responses in patients not previously responding to ICT. Taken together, these studies suggest that the risk–benefit calculation may favor rechallenge after irAEs to date have primarily focused on one type of cancer such as melanoma, RCC, or lung cancer, or have provided limited clinical details on treatment, severity, or cancers-specific outcomes, including duration of response. Given that ICTs can induce prolonged responses in subsets of patients with cancer, we hypothesized that ICT rechallenge after irAEs would be not only safe in selected circumstances but may lead to augmented, durable responses. In this retrospective study, we report on a cohort of patients with RCC, UC, and prostate cancer, who underwent ICT rechallenge after moderate-to-severe irAEs and achieved improved, durable responses in a subset of patients with RCC and UC, with an acceptable safety profile and no fatal events.

METHODS

Medical records of patients with RCC, UC, and prostate cancer treated at MD Anderson Cancer Center (MDACC) from September 25, 2013, to June 1, 2020, were queried using a set of 202 pre-specified search terms covering ICT (including generic names, trade names, and chemical names) and a broad set of autoimmune diseases encompassing irAEs, including abbreviations (online supplemental table 1). Patients’ records were manually reviewed to confirm administration of ICT and documentation of irAEs, permanent discontinuation or rechallenge with ICT, grade of irAE by CTCAE, and treatment. Data on demographics and outcomes were also collected. The data cut-off date for survival was March 8, 2021. Patient and disease characteristics were summarized as median and range for continuous variables, and as number and percentage for categorical variables. Radiographic responses were screened by RECIST V.1.1 where available (ie, when measurements were formally listed as part of a clinical protocol); otherwise, the response assessment of the treating physician was used. Response upgrades were subsequently confirmed by two independent radiologists by RECIST V.1.1. The decision to rechallenge with ICT was at the discretion of the treating physician. All statistics were descriptive in nature and no formal statistical hypotheses were tested. Kaplan-Meier survival curves were generated in GraphPad Prism V.8.0.0. Median follow-up time was calculated by the reverse Kaplan-Meier method.

RESULTS

In the initial screen, 30,681 patient records were queried using pre-specified search terms (online supplemental table 1), filtered to 231 patients with RCC, UC, or prostate cancer who experienced irAEs after ICT requiring suspension of treatment (figure 1). Sixty-one patients were identified who were rechallenged with the same or different ICT (RCC, n=28; UC, n=14; prostate cancer, n=19) (figure 1) (table 1). Eight of the 19 patients with prostate cancer (42%) had RECIST-measurable disease (table 1). Thirty-eight out of the 61 patients (62%) were rechallenged with their original ICT (ICT1) (online supplemental table 2). A subset of patients were rechallenged with a separate, second (‘ICT2’) or third (‘ICT3’) ICT agent, with overlaps between these groups, that is, patients who were rechallenged with both ICT1 and ICT2 (table 2). The relationship between the initial ICT drug class to the next line ICT exposure is provided in online supplemental table 3. Details of the reasons for ICT1 discontinuation are provided in online supplemental
The median time from first dose of ICT1 to discontinuation (last dose of ICT1) was 84 days (95% CI: 65 to 105).

The 61 patients rechallenged with ICT had experienced a total of 105 initial irAEs (table 3). The median time to the development of irAEs from ICT1 was 56 days (95% CI: 42 to 65). The majority of initial irAEs were moderate (grade 2) and included a subset of severe irAEs (grade 3 or 4). The most common irAEs of any grade were rash/pruritus, colitis/diarrhea, and thyroid abnormalities. The grade 3 irAEs consisted of rash/pruritus, colitis/diarrhea, hepatitis/elevated aspartate aminotransferase/alanine aminotransferase (AST/ALT), arthritis/arthralgia, pancreatitis, elevated amylase/lipase, and dyspnea/pleural effusion (table 3). There was one grade 4 irAE: hepatitis/elevated AST/ALT (table 3). There were no cases of the more often lethal cardiac or neuromuscular irAEs (myocarditis, myositis, or myasthenia gravis) in the cohort of patients rechallenged with ICT. Corticosteroids were administered in 54% of patients (33/61), and 21% of patients received targeted immunosuppression (13/61) for the initial irAEs (online supplemental table 5). Targeted immunosuppression included mesalamine, vedolizumab, infliximab, tocilizumab, and mycophenolate mofetil.

Thirty-six out of the 61 patients rechallenged with ICT (59%) experienced a total of 46 subsequent irAEs (table 3). The median time to first subsequent irAE after rechallenge was 116 days (95% CI: 56 to 268). Sixteen patients (26%) had recrudescence of the same irAE. Similar recrudescence rates were observed with rechallenge after grade 2 irAEs (26%, 9/34) and after grade 3/4 irAEs (20%, 3/15) (p=0.73, Fisher’s exact test). The rate of irAEs after rechallenge in patients who received corticosteroids for the initial irAE was 58% (19/33), and 61% (17/28) in those patients who did not receive corticosteroids. Most subsequent irAEs were grade 1 or grade 2 (table 3). The most common subsequent irAEs were rash/pruritus, colitis/diarrhea, and hepatitis/elevated AST/ALT (table 3). The breakdown of subsequent irAEs by rechallenge agent is provided in online supplemental table 7, and had an expected distribution (ie, colitis/diarrhea occurred most frequently following rechallenge with anti-GTLA-4-based regimens). There were 14 subsequent grade 3 irAEs (30%), including colitis/diarrhea, hepatitis/elevated AST/ALT, arthritis/arthritis, pneumonitis, adrenal insufficiency, and type 1 diabetes mellitus.

Table 1, Baseline characteristics of patients rechallenged with immune checkpoint therapy (ICT)

| Table 1 Continued | ICT rechallenge patients (n=61) |
|---|---|
| Enzalutamide | 8 (42) |
| Any NHT | 18 (95) |
| IMDC, International Metastatic RCC Database; MVAC, methotrexate, vinblastine, doxorubicin, and cisplatin; NHT, next-generation hormonal therapy; RCC, renal cell carcinoma. |

Continued
Eight of these 14 (57%) received systemic corticosteroids, with a median duration of steroids of 39 days (range: 15–69). There were no grade 4 or 5 irAEs. The relationship between type and grade of initial and subsequent irAEs is shown in figure 2. The most common initial irAEs leading to a subsequent irAE after rechallenge were colitis and rash (figure 2). One episode of grade 3 colitis was noted after an initial episode of grade 1 colitis, and cases of grade 3 hepatitis and colitis were identified after a grade 1 rash (figure 2). No cases of subsequent cardiac or neuromuscular irAEs (myocarditis, myositis, or myasthenia gravis) were observed in patients rechallenged with ICT.

We next examined efficacy outcomes with ICT rechallenge (figure 3). As of the March 8, 2021, data cut-off, the median follow-up time was 40.9 months (95% CI 35.3 to 46.5). The median time from first irAE to assessment of best radiographic response following rechallenge was 4.3 months (95% CI: 3.2 to 6.5). Survival outcomes are summarized in figure 3 and online supplemental table 8. Response upgrades were confirmed by two independent radiologists by RECIST V.1.1, and measurements for patients with upgrade in response are provided in online supplemental table 9. For the patients with RCC, three patients achieved a subsequent complete response (CR) from partial response (PR) after ICT rechallenge, and one patient reached a subsequent PR from stable disease (SD) (14%, 4/28) (figure 3C) (online supplemental table 4 and online supplemental table 9). In the patients with UC (n=14), three patients achieved CR from SD, including one patient (#60) who had undergone a consolidative surgery to resect residual tumor (21%, 3/14) (figure 3C) (online supplemental table 4 and online supplemental table 9). Among the patients with prostate cancer (eight patients with RECIST-measurable disease) no patients achieved an upgrade in response following ICT rechallenge (figure 3C) (online supplemental table 9). Details of the seven patients with UC and RCC who achieved an upgrade in response, all of whom had initial grade 2 or 3 irAEs, are summarized in table 4 and online supplemental table 10. One of these seven patients discontinued treatment for toxicity, one remains on treatment, and the
remainder either completed treatment as pre-specified in a clinical protocol or were lost to follow-up (table 4). The median progression-free survival (PFS) has not yet been reached for these seven patients (range: 3.7–66.4 months) (figure 3D). The patient with the shortest PFS (3.7 months, #13) was lost to follow-up and had achieved a PR at the time of last response assessment (figure 3D).

Among these seven patients, three patients had recurrence of the same irAE after rechallenge. Subsequent irAEs among these patients were predominantly grade 1 and 2, with the exception of grade 3 hepatitis in one patient who achieved a subsequent CR after PR (table 4). Finally, clinical information on the four patients who demonstrated a ‘downgrade’ in response, is provided in online supplemental table 11.

We then examined the influence of targeted immunosuppression (including biologics) on outcomes and identified 13 cases in which selective treatment enabled ICT rechallenge (RCC, n=7; UC, n=3; prostate cancer, n=3) (table 5). Nine of these 13 (69%) had been treated with corticosteroids (table 5). These 13 cases included colitis/diarrhea, arthritis, psoriasis, and hepatitis. For colitis, patients received mesalamine, infliximab (anti-tumor necrosis factor-α) and/or vedolizumab (anti-integrin α4β7) (table 5). Two patients with arthritis received tocilizumab (anti-interleukin (IL)-6), and one patient with psoriasis received secukinumab (anti-IL-17A) (table 5). There were seven subsequent irAEs, predominantly grade 1 or 2 with the exception of one grade 3 colitis. Notably, two patients with RCC achieved a subsequent response.

| Table 3 | Initial and subsequent irAEs in patients rechallenged with ICT |
|---------|---------------------------------------------|
| **Initial irAEs** | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Total |
| | N (%) | N (%) | N (%) | N (%) | N (%) |
| All | 105 (100) |
| Rash/pruritus | 15 (14) | 12 (11) | 4 (4) | 0 (0) | 31 (30) |
| Colitis/diarrhea | 5 (5) | 9 (9) | 7 (7) | 0 (0) | 21 (20) |
| Hypothyroidism/hyperthyroidism/thyroiditis | 1 (1) | 14 (13) | 0 (0) | 0 (0) | 15 (14) |
| Hepatitis/elevated AST/ALT | 5 (5) | 2 (2) | 1 (1) | 1 (1) | 9 (9) |
| Arthritis/arthralgia | 3 (3) | 4 (4) | 1 (1) | 0 (0) | 8 (8) |
| Hypophysitis | 0 (0) | 4 (4) | 0 (0) | 0 (0) | 4 (4) |
| Pancreatitis | 0 (0) | 3 (3) | 1 (1) | 0 (0) | 4 (4) |
| Pneumonitis | 2 (2) | 2 (2) | 0 (0) | 0 (0) | 4 (4) |
| Elevated amylase/lipase | 0 (0) | 1 (1) | 1 (1) | 0 (0) | 2 (2) |
| Adrenal insufficiency | 0 (0) | 1 (1) | 0 (0) | 0 (0) | 1 (1) |
| Dyspnea/pleural effusion | 0 (0) | 0 (0) | 1 (1) | 0 (0) | 1 (1) |
| Eosinophilia | 0 (0) | 1 (1) | 0 (0) | 0 (0) | 1 (1) |
| Hypersensitivity reaction | 0 (0) | 1 (1) | 0 (0) | 0 (0) | 1 (1) |
| Polymyalgia rheumatica | 0 (0) | 1 (1) | 0 (0) | 0 (0) | 1 (1) |
| Psoriasis | 0 (0) | 1 (1) | 0 (0) | 0 (0) | 1 (1) |
| Uveitis | 0 (0) | 1 (1) | 0 (0) | 0 (0) | 1 (1) |
| **Subsequent irAEs** | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Total |
| | N (%) | N (%) | N (%) | N (%) | N (%) |
| All | 46 (100) |
| Rash/pruritus | 10 (22) |
| Colitis/diarrhea | 8 (17) |
| Hypothyroidism/hyperthyroidism/thyroiditis | 8 (17) |
| Hepatitis/elevated AST/ALT | 6 (13) |
| Arthritis/arthralgia | 8 (17) |
| Hypothyroidism | 4 (9) |
| Pneumonitis | 3 (7) |
| Adrenal insufficiency | 2 (4) |
| Type 1 diabetes mellitus | 2 (4) |
| Pancreatitis | 1 (2) |
| Peripheral neuropathy | 1 (2) |
| Nephritis | 1 (2) |

All events graded by Common Terminology Criteria for Adverse Events (CTCAE) V.5. ALT, alanine aminotransferase; AST, aspartate aminotransferase.
upgrade with selective immunosuppression (SD to PR, n=1; PR to CR, n=1), who had colitis/diarrhea, of whom one received vedolizumab and one received mesalamine (table 5). Of these 13 patients, 7 experienced a subsequent irAE (54%), which were predominantly grade 1 or 2, with the exception of one subsequent case of grade 3 colitis/diarrhea, which occurred following rechallenge with anti-CTLA-4 monotherapy after grade 1 colitis/diarrhea (table 5). Corticosteroids were required in two of these seven cases (29%). Vedolizumab was employed in one case of grade 3 colitis, and tocilizumab was employed in two cases of grade 1 and grade 2 arthritis/arthralgia, respectively (table 5).

Finally, because it has recently been observed that irAE involvement in target organs (eg, interstitial nephritis in patients with RCC) may be associated with increased response to ICT, potentially due to antigenic overlap between renal tubular cells and tumor cells, we identified one patient with RCC, who had grade 2 nephritis as a subsequent irAE after initial grade 2 uveitis. This patient achieved a durable partial response lasting 30 months from the start of ICT, with a time to subsequent treatment of 25.9 months.

DISCUSSION

In this retrospective cohort study, we investigated ICT rechallenge following moderate-to-severe irAEs in patients with RCC, UC, and prostate cancer. We hypothesized that ICT rechallenge after irAEs would be safe in selected circumstances and could lead to augmented, durable responses. We observed that ICT rechallenge after moderate-to-severe irAEs was associated with deep and durable responses in a subset of patients with RCC and UC, with an acceptable safety profile and no fatal events.

For patients with treatment-refractory cancers and limited therapeutic options, the ability to rechallenge
with ICT offers a potential strategy for clinical benefit. Prior studies have reported an acceptable rate of irAE recrudescence following ICT rechallenge in selected circumstances with additional antitumor responses in certain cases (online supplemental table 10). 

Figures 3

**Figure 3** Outcomes with ICT rechallenge. (A) Progression-free survival (PFS) after first exposure to ICT (ICT1). Initial screening radiographic response assessment obtained per RECIST V.1.1 where available. Radiographic PFS (rPFS) used for patients with prostate cancer. (B) Overall survival (OS) after ICT1. (C) Best radiographic response after irAE. irAEs are annotated for seven patients (four RCC and three UC) with response upgrade. Response upgrades confirmed by two independent radiologists. (D) Swimmer’s plot of PFS after ICT1 (months) in patients with response upgrades. Response upgrades confirmed by two independent radiologists. Yellow arrows indicate ongoing response. CR, complete response; CTLA-4, cytotoxic T lymphocyte-associated protein-4; ICT, immune checkpoint therapy; irAE, immune-related adverse event; PD, progression of disease; PD-1 programmed cell death protein-1; PD-L1, programmed death-ligand 1; PR, partial response; RCC, renal cell carcinoma; SD, stable disease; TKI, tyrosine kinase inhibitor; UC, urothelial carcinoma. *Indicates patient who underwent consolidative surgery.

Beyond the issue of safety, a key question is whether ICT rechallenge after irAEs is associated with improved outcomes. In a retrospective study of 173 patients with metastatic melanoma who developed gastrointestinal (GI) irAEs, any grade GI irAEs were associated with improved OS compared with patients who did not experience GI irAEs, with no impact on survival with the use of immunosuppressive treatment. 

Moreover, evidence suggests that ICT rechallenge may lead to an antitumor effect for patients with irAEs who had not previously experienced a toxic response, as has been shown in non-small cell lung cancer and melanoma. 

Two separate studies of ICT rechallenge in RCC have reported objective response rates of 23%. These studies included subsets of patients with grade 3 toxicities, but did not provide information on immunosuppression beyond corticosteroids. In our patients, we observed objective response rates of 14% in RCC, 21% in UC, and 0% in prostate cancer (in eight patients with RECIST-measurable disease) following ICT rechallenge. It is important to note that ICT is not
Table 4  Clinical information for patients who achieved subsequent upgrade in response after ICT rechallenge

| Pt. | Age | Sex | Cancer | Alive | OS from ICT1 (Mo.) | ICT 1 | Imaging response pre-ICT1 and post-ICT1 | PFS from ICT1 (Mo.) | Initial irAE | Initial irAE grade | Steroid | Other immunosupp. | Other initial irAE | ICT rechall. drug | Reason ICT1 stopped | Imaging response pre-rechall. and post-rechall. | Same irAE after rechall. | Subseq. irAE |
|-----|-----|-----|--------|-------|-------------------|-------|----------------------------------------|-------------------|-------------|----------------|----------|----------------|----------------|----------------|-------------------|----------------------------------------|------------------|-------------|
| 13  | 65  | M   | RCC    | LTFU  | 6                 | Anti-PD-(L)1 | PR* | 3.7 | Colitis/diarrhea | 3 | Y | Vedo. | None | Anti-PD-(L)1 | Therapy complete | LTFU | PR* | N | NA |
| 51  | 42  | M   | RCC    | LTFU  | 21                | Anti-CTLA-4+Anti-PD-(L)1 | PR | 19.6 | All (HC) | 2 | Y (HC) | N/A | Thyroiditis (G2) rash/pruritus | Anti-PD-(L)1 | Therapy complete | OR | Y | Arthralgia (G1) |
| 52  | 87  | M   | UC     | Y     | 40.5              | Anti-PD-(L)1 | SD | 40.3 | Arthralgia | 2 | Y | N/A | None | Anti-PD-(L)1 | Therapy complete | OR | Y | Arthralgia (G2) |
| 57  | 56  | M   | RCC    | Y     | 40.9              | Anti-PD-(L)1+TKI | PR | 37.9 | Colitis/diarrhea | 2 | Y | Mes. | Rash/pruritus (G1) | Anti-PD-(L)1+TKI | Therapy ongoing | OR | Y | Diarrhea (G1) |
| 59  | 41  | M   | UC     | Y     | 46                | Anti-CTLA-4+Anti-PD-(L)1 | SD | 37.3 | Colitis/diarrhea | 3 | Y | N/A | None | Anti-CTLA-4+Anti-PD-(L)1 | Therapy complete | CR* | N | Rash (G1) |
| 60  | 72  | M   | UC     | Y     | 60.8              | Anti-CTLA-4 | SD | 60.6 | Colitis/diarrhea | 3 | Y | N/A | Rash/pruritus (G1) | Anti-CTLA-4 | Therapy complete | CR | N | NA |
| 61  | 54  | F   | RCC    | Y     | 66.5              | Anti-CTLA-4+Anti-PD-(L)1 | PR | 66.4 | Pneumonitis | 2 | Y | N/A | Thyroiditis (G2) | Anti-CTLA-4 | Toxicity | CR | N | Hepatitis (G3) |

*First restaging imaging occurred after irAE.

AI, adrenal insufficiency; CR, complete response; CTLA-4, cytotoxic T lymphocyte-associated protein-4; HC, hydrocortisone; ICT, immune checkpoint therapy; Immunosupp., immunosuppression; irAE, immune-related adverse event; LTFU, lost to follow-up; Mes, mesalamine; Mo., month; OS, overall survival; PD-L1, programmed death-ligand 1; PFS, progression-free survival; PR, partial response; Pt, patient; RCC, renal cell carcinoma; rechall., rechallenge; SD, stable disease; subseq., subsequent; TKI, tyrosine kinase inhibitor; UC, urothelial carcinoma; Vedo, vedolizumab.
Table 5  Clinical details of ICT rechallenged patients who received targeted immunosuppression for initial irAE

| Pt. | Age | Sex | OS from ICT1 (Mo.) | PFS from ICT1 (Mo.) | Primary cancer | ICT1 | Initial irAE | Initial irAE steroid | Other immune suppression for initial irAE | ICT rechallenge drug | Imaging response after rechallenge | Same irAE after rechallenge | Subs. irAE | Subs. irAE grade | Other immune suppression for subs. irAE |
|-----|-----|-----|--------------------|---------------------|-----------------|-------|--------------|---------------------|----------------------------------------|----------------------|-------------------------------------|--------------------------|----------|---------------|-----------------------------------|
| 16  | 53  | M   | 19.6               | 4.8                 | RCC             | Anti-CTLA-4+Anti-PD-(L)1 | Hepatitis | 4               | Yes                  | Mycophenolate mofetil                | Anti-PD-(L)1+TKI       | PR                        | No                        | Hypothyroid | 2             | None                               |
| 47  | 50  | M   | 30.7               | 10.4                | RCC             | Anti-CTLA-4+Anti-PD-(L)1+TKI | Colitis/diarrhea | 3               | Yes                  | Vedolizumab+FMT                    | Anti-PD-(L)1 monotherapy | PD                        | No                        | None          | None          | None                               |
| 9   | 49  | M   | 10.9               | 3                   | RCC             | Anti-CTLA-4 monotherapy | Colitis/diarrhea | 3               | Yes                  | Infliximab                          | Anti-PD-(L)1+TKI       | PD                        | No                        | None          | None          | None                               |
| 43  | 50  | M   | 28.9               | 12.5                | RCC             | Anti-PD-(L)1+other | Colitis/diarrhea | 2               | Yes                  | Vedolizumab                          | Anti-PD-(L)1+TKI       | PR                        | No                        | Hepatitis    | 2             | None                               |
| 57  | 56  | M   | 34.6               | 33.4                | RCC             | Anti-PD-(L)1+TKI | Colitis/diarrhea | 2               | Yes                  | Mesalamine                          | Anti-PD-(L)1+TKI       | CR                        | Yes                       | Colitis/diarrhea | 1             | None                               |
| 13  | 65  | M   | 6                  | 3.7                 | RCC             | Anti-PD-(L)1 monotherapy | Colitis/diarrhea | 3               | Yes                  | Vedolizumab                          | Anti-PD-(L)1 monotherapy | PR                        | No                        | None          | None          | None                               |
| 38  | 59  | M   | 16.8               | 10.3                | RCC             | Anti-PD-(L)1+TKI | Colitis/diarrhea | 1*               | Yes                  | Infliximab                          | Anti-PD-(L)1+TKI       | SD                        | No                        | None          | None          | None                               |
| 49  | 68  | F   | 27.3               | 10.5                | UC              | Anti-CTLA-4+Anti-PD-(L)1 | Psoriasis     | 2               | No                   | Secukinumab                          | Anti-PD-(L)1           | CR                        | No                        | None          | None          | None                               |
| 42  | 64  | M   | 26.6               | 12.5                | UC              | Anti-PD(L)1+other | Arthritis      | 2               | Yes                  | Tocilizumab                          | Anti-PD-(L)1+other     | PR                        | Yes                       | Arthralgia   | 1             | Tocilizumab                         |
| 34  | 70  | F   | 25.3               | 22.2                | UC              | Anti-PD(L)1+other | Arthritis      | 2               | Yes                  | Tocilizumab                          | Anti-PD-(L)1+other     | SD                        | Yes                       | Arthralgia   | 2             | Tocilizumab                         |
| 3   | 47  | M   | 20.2               | 2.1                 | Prostate cancer | Anti-CTLA-4+Anti-PD-(L)1 | Colitis/diarrhea | 2               | No                   | Mesalamine                          | Anti-PD-(L)1           | PD                        | No                        | None          | None          | None                               |
| 22  | 76  | M   | 16.5               | 7.1                 | Prostate cancer | Anti-CTLA-4 monotherapy | Colitis/diarrhea | 1               | No                   | Mesalamine                          | Anti-CTLA-4            | SD                        | Yes                       | Colitis/diarrhea | 3             | Vedolizumab                         |
| 2   | 55  | M   | 13.1               | 1.8                 | Prostate cancer | Anti-CTLA-4+Anti-PD-(L)1 | Colitis/diarrhea | 1               | No                   | Mesalamine                          | Anti-CTLA-4+anti-PD-(L)1 | PD                        | Yes                       | Pneumonitis colitis/diarrhea | 2             | None                               |

*Patient treated with infliximab for persistent symptoms despite steroids.

CR, complete response; CTLA-4, cytotoxic T lymphocyte-associated protein-4; FMT, fecal microbiota transplantation; ICT, immune checkpoint therapy; irAE, immune-related adverse event; Mo., month; OS, overall survival; PD, progressive disease; PD-(L)1, programmed death-ligand 1; PFS, progression free survival (radiographic PFS for prostate cancer); PR, partial response; Pt., patient; RCC, renal cell carcinoma; SD, stable disease; Subs., subsequent; TKI, tyrosine kinase inhibitor; UC, urothelial carcinoma.
approved by the Food and Drug Administration for prostate cancer except in certain tumor-agnostic settings, and significant effort is underway in optimizing patient selection (including sites of disease, e.g., bone-predominant vs lymph node vs visceral metastases). All seven patients who achieved a subsequent upgrade in response had experienced grade 2 or 3 irAEs. Two patients with RCC achieved a response upgrade following selective immunosuppression after grade 2 or 3 colitis. Most notably, these responses were durable and deep, with median PFS not yet reached as of the March 8, 2021, data cut-off date, and six of the seven patients achieving CR. The patient with the shortest PFS had a partial response at the time of last response assessment and was lost to follow-up. Notably, while the classes of second-line ICTs in our cohort were diverse, among those patients with upgrade in response, all of the patients were rechallenged with a similar class of drug or only one of the two drugs (eg, anti-PD-(L)1 following anti-CTLA-4 plus anti-PD-(L)1). Taken together, these results suggest that ICT rechallenge may be associated with deep and durable benefit for certain patients.

Recent evidence has suggested that distinct mechanisms may be involved in antitumor immunity compared with irAEs, which may permit selective immunosuppression with steroid-sparing approaches and continuation of ICT. In one case of colitis treated with vedolizumab in our cohort, the patient achieved PR from SD after rechallenge, and the use of secukinumab enabled ICT treatment in a patient with psoriasis who achieved CR. Notably, this approach enabled ICT rechallenge after selected severe irAEs. Clinical trials investigating the role of targeted immunosuppression in irAEs are ongoing, including trials at our institution of infliximab, vedolizumab, and fecal microbiota transplantation in ICT-associated colitis (NCT04407247, NCT04038619). Furthermore, investigation into mechanisms of irAEs remains a highly active area of research to identify rational therapeutic targets and predictive biomarkers (eg, the presence of autoantibodies or clonally expanded peripheral T cells) to identify at-risk patients for early intervention.

The major strengths of our study are the inclusion of multiple tumor types (including urothelial carcinoma which has had less data on ICT rechallenge than RCC), comparable sample size to other major studies of ICT rechallenge, and detailed clinical information on severity (with the majority of cases being moderate and including a subset of severe cases), treatment (including selective immunosuppression), and outcomes (including duration of responses). We acknowledge that our study has several limitations, notably its retrospective nature and physician discretion regarding ICT discontinuation or rechallenge. As described above, the presence of irAEs alone in certain circumstances is associated with improved cancer outcomes; therefore, causality cannot necessarily be attributed to the ICT rechallenge. Due to the multiple factors contributing to the decision to discontinue versus rechallenge ICT, including differences in the distribution of irAEs (including type and grade) an accurate comparison of clinical responses between the two groups is not feasible, outside of the context of a prospective clinical trial. This is particularly important in two patients, one of whom also received consolidative surgery (#59) and one whose first response assessment occurred after the development of the irAE (#13), which limits conclusions as to the benefit of ICT rechallenge in these two patients. Additionally, as irAEs were screened using specified search terms and subsequently confirmed by manual chart review, the reports rely on the accurate recording and documentation of irAEs by the treating physician.

Finally, we did not have patients rechallenged with ICT who experienced toxicities that carry a particularly high mortality rate, such as myocarditis, myositis, and myasthenia gravis.

In conclusion, in this retrospective analysis of patients with genitourinary cancers (prostate, kidney, and bladder), ICT rechallenge after moderate-to-severe irAEs was associated with deep and durable responses in a subset of patients with RCC and UC, with an acceptable safety profile and no fatal events. Strategies to enable ICT resumption following moderate-to-severe irAEs, such as with targeted immunosuppression warrant further study.
Bristol Myers Squibb, Merck, Mirati, Nektar, Seattle Genetics, Taiho, Janssen, Immunomedics; Research Funding: Basilea, Bristol Myers Squibb, Merck, Nektar, Janssen, Immunomedics. PS reports Stock/Other Ownership: Achelols, Adaptive Biotechnologies, Affini-T, Apricity Health, BioAlta, BioTechNet, Codak Biosciences, Constellation, Dragonfly Therapeutics, Earl, Glympe, Hummingbird Biosciences, ImaginAB, Infinity Pharma, Jounee Therapeutics, JSL Health, Lava Therapeutics, Lytx Biopharma, Marker Therapeutics, Oncolytics, PBM Capital, Phenomics, Polaris Group, Sporos, Time Bioventures, Consulting/Advisory Role: Achelols, Affini-T, Apricity Health, BioAlta, Codak Biosciences, Dragonfly Therapeutics, Earl, Glympe, Hummingbird Biosciences, ImaginAB, Infinity Pharma, Jounee Therapeutics, JSL Health, Lava Therapeutics, Lytx Biopharma, Marker Therapeutics, Oncolytics, PBM Capital, Phenomics, Polaris Group, Sporos, Time Bioventures. SKS reports Stock and Other Ownership Interests: Apricity Health; Honoraria: Apricity Health, Janssen, Dendreon, Polaris, Parker Institute of Cancer Immunotherapy, Amgen, AstraZeneca, Bayer, Bristol Myers Squibb, Dava Oncology, Exelixis, Society for Immunotherapy of Cancer; Consulting or Advisory Role: Valeant/Dendreon, Apricity Health, Janssen, Polaris, Bayer, Bristol Myers Squibb, Amgen, AstraZeneca, Dava Oncology; Research Funding: Janssen, Bristol Myers Squibb, AstraZeneca; Travel, Accommodations, Expenses: Janssen, Compugen, Dendreon, Amgen, Parker Institute for Cancer Immunotherapy, Bristol Myers Squibb, Society for Immunotherapy of Cancer, AstraZeneca, Dava Oncology, NMT reports consulting/advisory relationship: Bristol Myers Squibb; Pfizer; Nektar Therapeutics; Exelixis, Eisai Medical Research; Eli Lilly; Oncorena; Calithera Biosciences; Surface Oncology; Novartis, Ipsen; Merck Sharp & Dohme; Research Funding: Bristol Myers Squibb; Nektar Therapeutics; Calithera Biosciences; Arrowhead Pharmaceuticals; Scientific Advisory Committees: Nektar Therapeutics; Pfizer; Oncorena; Eli Lilly, Eisai Medical Research.

Patient consent for publication Not required.

Ethics approval This study was conducted under an Institutional Review Board approved protocol (PA16-0736) covering retrospective chart reviews in the Department of Genitourinary Medical Oncology at the University of Texas MD Anderson Cancer Center (MDACC).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Bilal A Siddiqui http://orcid.org/0000-0002-6806-1294

REFERENCES

1. Hasanov E, Gao J, Tannir NM. The immunotherapy revolution in kidney cancer treatment: scientific rationale and first-generation results. Cancer J 2020;26:419–31.
2. Siefker-Radtké A, Curti B. Immunotherapy in metastatic urothelial carcinoma: focus on immune checkpoint inhibition. Nat Rev Urol 2018;15:112–24.
3. Brahmher JR, Laccetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of clinical oncology clinical practice guideline. J Clin Oncol 2018;36:1714–68.
4. Maher VE, Fernandes LL, Weinstock C, et al. Analysis of the association between adverse events and outcome in patients receiving a programmed death protein 1 or programmed death ligand 1 antibody. J Clin Oncol 2019;37:2730–7.
5. Indini A, Di Guardo L, Cimiriniello C, et al. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol 2019;145:511–21.
6. Xing P, Zhang F, Wang Y, et al. Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPi: a systematic review and meta-analysis. J Immunother Cancer 2019;7:341.
7. Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer 2019;7:306.
8. Riudavets M, Mosquera J, Garcia-Campelo R, et al. Immune-related adverse events and corticosteroid use for cancer-related symptoms are associated with efficacy in patients with non-small cell lung cancer receiving anti-PD-L1 blockade agents. Front Oncol 2020;10:1677.
9. Rogado J, Sánchez-Torres JM, Romero-Laorden N, et al. Immune-Related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer 2019;109:21–7.
10. Toi Y, Sugawara S, Kawashima Y, et al. Association of immune-related adverse events with clinical benefit in patients with advanced non-small-cell lung cancer treated with nivolumab. Oncologist 2018;23:1358–65.
11. Okada N, Kawazoe H, Takechi K, et al. Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with nivolumab: a multicenter retrospective study. Clin Ther 2019;41:59–67.
12. Elias R, Yan F, Singla N, et al. Immune-related adverse events are associated with improved outcomes inICI-treated renal cell carcinoma patients. JCO 2019;37:845.
13. Grangeon M, Tomasini P, Chaleat S, et al. Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung cancer. Clin Lung Cancer 2019;20:201–7.
14. Sato K, Akamatsu H, Murakami E, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 2018;115:71–4.
15. Mian I, Yang M, Zhao H, et al. Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab. JCO 2016;34:3047.
16. Owen DH, Wei L, Bertino EM, et al. Incidence, risk factors, and effect on survival of immune-related adverse events in patients with non-small-cell lung cancer. Clin Lung Cancer 2018;19:e893–900.
17. Horvat TZ, Adel NG, Dag T-O, et al. Immune-Related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at Memorial Sloan Kettering cancer center. J Clin Oncol 2015;33:3193–8.
18. Ricciuti B, Genova C, De Giglio A, et al. Impact of immune-related adverse events in metastatic renal cell carcinoma. J Immunother Cancer 2019;7:201–7.
19. Esfahani K, Elkon R, Prabhu KD, et al. Treatment-related immune adverse events: review of the literature and suggested prophylactic strategies. JAMA Oncol 2019;5:1806.
20. Abou Alaiwi S, Xie W, Nassar AH, et al. Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma. J Immunother Cancer 2020;8:e00144–11.
21. Ravi P, Mantia C, Su C, et al. Evaluation of the safety and efficacy of immunotherapy rechallenge in patients with renal cell carcinoma. JAMA Oncol 2020;6:1606.
22. Haansen J, Ernstoff M, Wang Y, et al. Rechallenge patients with immune checkpoint inhibitors following severe life-threatening immune-related adverse events: review of the literature and suggested prophylactic strategy. J Immunother Cancer 2020;8:e000604.
23. Herbst RS, Garon EB, Kim D-W, et al. Long-Term outcomes and retreatment among patients with previously treated, programmed Death-Ligand 1–Positive, advanced Non-Small-Cell lung cancer in the KEYNOTE-010 study. J Clin Oncol 2020;38:1580–90.
24. Patel V, Elias R, Formella J, et al. Acute interstitial nephritis, a potential predictor of response to immune checkpoint inhibitors in renal cell carcinoma. J Immunother Cancer 2020;8:e001198.
25. Dalladle C, Ederyh S, Sassiex M, et al. Immune checkpoint inhibitor rechallenge after immune-related adverse events in patients with cancer. JAMA Oncol 2020;6:865–7.
26. Simonaggio A, Michot JM, Voisine AL, et al. Evaluation of Readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer. JAMA Oncol 2019;5:1310–7.
27 Santini FC, Rizvi H, Plodkowski AJ, et al. Safety and efficacy of Re- treating with immunotherapy after immune-related adverse events in patients with NSCLC. *Cancer Immunol Res* 2018;6:1093–9.

28 Menzies AM, Johnson DB, Ramanujam S, et al. Anti-Pd-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. *Ann Oncol* 2017;28:368–76.

29 Pollack MH, Betof A, Dearden H, et al. Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma. *Ann Oncol* 2018;29:250–5.

30 Allouchery M, Lombard T, Martin M, et al. Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer. *J Immunother Cancer* 2019;8(4):e001622.

31 Abu-Sbeih H, Ali FS, Qiao W, et al. Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. *Cancer Immunol Immunother* 2019;68:553–61.

32 Motzer RJ, Escudier B, McDermott DF, et al. Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial. *J Immunother Cancer* 2020;8:e000891.

33 Sharma P, Pachynski RK, Narayan V, et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. *Cancer Cell* 2020;38:489–99.

34 Gao J, Shi LZ, Zhao H, et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. *Cell* 2016;167:397–404.

35 Grasso CS, Tsiol J, Onyshchenko M, et al. Conserved interferon-γ signaling drives clinical response to immune checkpoint blockade therapy in melanoma. *Cancer Cell* 2020;38:500–15.

36 Luoma AM, Suo S, Williams HL, et al. Molecular pathways of colon inflammation induced by cancer immunotherapy. *Cell* 2020;182:655–71.

37 Subudhi SK, Aparicio A, Gao J, et al. Clonal expansion of CD8 T cells in the systemic circulation precedes development of ipilimumab-induced toxicities. *Proc Natl Acad Sci U S A* 2016;113:11919–24.

38 Tahir SA, Gao J, Miura Y, et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. *Proc Natl Acad Sci U S A* 2019;116:22246–51.